Prevymis is a member of a new class of drugs called non-nucleoside CMV inhibitors.
News
Novartis hits targets in late-stage QMF149 asthma trial
The once-daily, fixed-dose treatment demonstrated significant improvements in lung function and asthma control.
BMJ study shows correlation between processed foods and CV disease
Cardiovascular disease is the main cause of death worldwide, representing one third of all deaths globally.
NICE issues guidance revision for depression
The governing body has been urged to undergo a “full and proper revision” of its 2009 guideline on adult depression.
Milestone achieved in J&J’s investigational HIV study
Johnson & Johnson has announced full enrolment in its proof-of-concept efficacy study of Imbokodo.
NHS to launch new online type II diabetes support
The new online portal will offer people with type II diabetes evidence-based information and support.
Record number of cancer drugs launched in 2018, says report
The IQVIA report also explores health system barriers hindering the realisation of the benefits of those therapies and drug candidates.
FDA breakthrough therapy designation granted for Bayer’s Aliqopa
The decision was primarily based on follow-up data from the pivotal Phase II study CHRONOS-1.
Univar’s Cufence leads latest CHMP decisions
The committee recommended four treatments including two generic medicines.
Sosei get $2.5m for QVM149 MAA
The company recently announced positive data from two Phase II clinical studies, in which QVM149 was shown to be superior to the comparators.
Positive late stage rheumatoid arthritis trial results for Abbvie
Upadacitinib was found to have achieved both primary endpoints with significantly higher rates of ACR20 response and low disease activity at week 14.
Inpatients seen within target time falls to 68% in Scotland
Professor Derek Bell of the Royal College of Physicians of Edinburgh spoke out against the worsening figures.
EMA gives trastuzumab biosimilar Marketing Authorisation Application
The drug is Prestige’s lead development candidate biosimilar to Roche’s Herceptin.
FDA approval for Novartis’ Piqray
The FDA approval is based on a Phase III trial, SOLAR-1, in which the combination nearly doubled median progression free survival.
Theresa May failed to tackle “country’s biggest injustices”, says NHS
Back in 2018 she announced that the NHS was to receive an extra £20 billion a year by 2023.
